Savvy Updates, 9/23/24: G7 Geofencing Fix, Senseonics Eversense 365, Abbott Ramps Libre3 Production, AI Predicts Retinopathy, SuperCell Medicines, Stem Cell-Enabled Therapy, How to Appeal Insurance Denial, T1D & Brain Development, FTC & PMBs Sue Each Other, ChatGPT for Diagnosis

Savvy Updates, 9/23/24: G7 Geofencing Fix, Senseonics Eversense 365, Abbott Ramps Libre3 Production, AI Predicts Retinopathy, SuperCell Medicines, Stem Cell-Enabled Therapy, How to Appeal Insurance Denial, T1D & Brain Development, FTC & PMBs Sue Each Other, ChatGPT for Diagnosis

Sep 23, 2024 | Diabetes Business, Research News, Technology Updates, Videos

In this week’s issue of The Savvy Diabetic:  Geofencing/Dexcom G7 Update! with Jake Leach Senseonics Gets FDA Clearance for 1-year CGM Abbott Ramps Up Libre 3 Production AI Model to Predict Diabetic Retinopathy GC Therapeutics “Supercell”...
Savvy Updates 7/1/24: Senseonics 365-day CGM, Dana Lewis on Exocrine Pancreatic Insufficiency, Apple/Fitbit/Garmin & Bacteria, Low-Dose SGLT2 Inhibitor May Protect Kidneys, Dual GLP-1 & Glucagon Agonist Pemvidutide, How GLP-1 Receptor Agonists Work

Savvy Updates 7/1/24: Senseonics 365-day CGM, Dana Lewis on Exocrine Pancreatic Insufficiency, Apple/Fitbit/Garmin & Bacteria, Low-Dose SGLT2 Inhibitor May Protect Kidneys, Dual GLP-1 & Glucagon Agonist Pemvidutide, How GLP-1 Receptor Agonists Work

Jul 1, 2024 | Diabetes Business, Podcasts, Research News, Technology Updates

Senseonics tips 365-day CGM to double 2025 sales by Nick Paul Taylor for MedTechDive.com, 25 June 2024. In 2024, Senseonics expects to more than double U.S. new patient starts and increase the global installed base by around 50%. The growth is built on the current...
Savvy Updates, 8/14/23: Medicare Covers Libre 3, Senseonics Seeks iCGM Designation, 5000 Steps are Enough, New Bill to Expand Drug Negotiations Under Medicare, Chinese microbial DPP4, Green Space & Blood Pressure, GLP-1 Agonists & Retinopathy, Satisfy Your Sweet Tooth, Take an Insulin Pump Vacation – Be Prepared

Savvy Updates, 8/14/23: Medicare Covers Libre 3, Senseonics Seeks iCGM Designation, 5000 Steps are Enough, New Bill to Expand Drug Negotiations Under Medicare, Chinese microbial DPP4, Green Space & Blood Pressure, GLP-1 Agonists & Retinopathy, Satisfy Your Sweet Tooth, Take an Insulin Pump Vacation – Be Prepared

Aug 14, 2023 | Diabetes Business, Eating, Featured, Foods, Research News, Technology Updates, Videos

Medicare Covers FreeStyle Libre 3 CGM by Andrew Briskin and April Hopcroft for diaTribe.org, 4 August 2023. Abbott has announced that its latest continuous glucose monitor, the FreeStyle Libre 3, is now covered under Medicare.  Following news in April that...
Savvy Updates, 9/6/22: Senseonics CFO Leaves, Beta Bionics Trial Data & RIF, Chip-free, Wireless Electronic Skin, Insulin Pill, Cognitive Benefits from Hybrid Closed Loop Systems, Sugar & Microbiome, T1D & Hypothyroidism

Savvy Updates, 9/6/22: Senseonics CFO Leaves, Beta Bionics Trial Data & RIF, Chip-free, Wireless Electronic Skin, Insulin Pill, Cognitive Benefits from Hybrid Closed Loop Systems, Sugar & Microbiome, T1D & Hypothyroidism

Sep 6, 2022 | Eating, Featured, Foods, Research News, Technology Updates

Senseonics Announces CFO Transition was published by Senseonics Holdings, Inc., 1 September 2022.   Senseonics, a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems...
Skip to content